Hourglass Capital LLC Has $7.12 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Hourglass Capital LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 47.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 67,435 shares of the medical equipment provider’s stock after purchasing an additional 21,560 shares during the period. Zimmer Biomet makes up approximately 2.0% of Hourglass Capital LLC’s portfolio, making the stock its 18th biggest holding. Hourglass Capital LLC’s holdings in Zimmer Biomet were worth $7,123,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at approximately $25,000. Dunhill Financial LLC grew its stake in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet during the 3rd quarter worth $28,000. Brooklyn Investment Group bought a new position in Zimmer Biomet during the 3rd quarter worth $35,000. Finally, Kentucky Trust Co acquired a new position in Zimmer Biomet during the 4th quarter worth about $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of analyst reports. Raymond James lowered their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Wells Fargo & Company increased their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Barclays dropped their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, JMP Securities restated a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $100.52 on Friday. The company has a market cap of $20.01 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90. The business has a 50 day moving average price of $106.34 and a 200-day moving average price of $107.72.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the firm posted $2.20 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.96%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.